| Business Summary | | Interneuron
Pharmaceuticals
Inc.
is
a
biopharmaceutical
company
engaged
in
the
development
and
commercialization
of
a
diversified
portfolio
of
product
candidates,
including
multiple
compounds
in
late-stage
clinical
development.
The
Company
is
currently
developing,
or
has
certain
rights
to,
five
compounds
in
clinical
development.
These
compounds
are
pagoclone
for
panic
and
generalized
anxiety
disorders,
trospium
for
overactive
bladder,
IP
501
for
cirrhosis
of
the
liver,
citicoline
for
ischemic
stroke,
and
PRO
2000
for
the
prevention
of
sexually
transmitted
diseases
and
human
immunodeficiency
virus
(HIV)
infection.
In
addition,
the
Company
has
other
compounds
in
earlier
stages
of
development,
including
pituitary
adenylate
cyclase
activating
polypeptide
(PACAP)
for
respiratory
diseases,
diabetes,
stroke
and
other
neurodegenerative
diseases. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IPIC
is
a
biopharmaceutical
company
engaged
in
the
development
and
commercialization
of
a
portfolio
of
products
primarily
for
neurological
and
behavioral
diseases.
For
the
nine
months
ended
6/30/01,
revenues
decreased
96%
to
$932
thousand.
Net
income
decreased
96%
to
$558
thousand.
Revenues
reflect
the
absence
of
license
fees
from
Pfizer
and
Takeda.
Net
income
also
reflects
increased
S/G/A
expenses
as
a
percentage
of
revenues. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Glenn Cooper, M.D., 48 Chairman,
Pres, CEO | $901K | -- | Michael Rogers, 40 Exec.
VP, CFO and Treasurer | 637K | -- | Mark Butler, 54 Exec.
VP, CAO and Gen. Counsel | 628K | $149K | Bobby Sandage, Jr., Ph.D., 47 Exec.
VP, R&D and CSO | 624K | -- | Dollar
amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|